Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options

详细信息    查看全文

• 作者：Ilaria Pagnini ; Federico Bertini ; Rolando Cimaz
• 刊名：Pediatric Drugs
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：18
• 期：2
• 页码：101-108
• 全文大小：440 KB
• 参考文献：1.Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–8.CrossRef PubMed
  2.Petty RE, Soutwood TR, Manners OP, Baum J, Glass DN, Goldenberg H, et al. International League of Association for Rheumatology classification of juvenile idiopathic arthritis: second version, Edmonton, 2001. J Rheumatol. 2004;31:390–2.PubMed
  3.Lovell DJ, Giannini EH, Reiff A, Cawkell GD, Silverman ED, Norton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763–9.CrossRef PubMed
  4.Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–106.CrossRef PubMed
  5.Silverman E, Mouy R, Spiegel L, Jung LK, Sautermann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655–66.CrossRef PubMed
  6.Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.CrossRef PubMed
  7.Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile idiopathic arthritis: results of the U.S.A.-U.R.S.S. double blind, placebo-controlled trial. N Engl J Med. 1992;326:1043–9.CrossRef PubMed
  8.Ruperto N, Murray KJ, Gerona V, Wulffrat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher draw in children with juvenile idiopathic arthritis who failed to response to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191–201.CrossRef PubMed
  9.Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62:1792–802.CrossRef PubMed
  10.Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005;294:1671–84.CrossRef PubMed
  11.Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–82.CrossRef
  12.Lovell DJ, Reiff A, Illowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1496–504.CrossRef PubMed
  13.Hayward K, Wallace CA. Recent development in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2009;11:216.CrossRef PubMed PubMedCentral
  14.Bartoli M, Tarò M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67:370–4.CrossRef PubMed
  15.Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pèrez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383–91.CrossRef PubMed
  16.Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomized, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–7.CrossRef PubMed PubMedCentral
  17.Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicenter randomized open-label clinical trial. Ann Rheum Dis. 2011;70:1605–12.CrossRef PubMed
  18.Ringold S, Weiss PF, Beukelman T, DeWitt EM, Illowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65:2499–512.CrossRef PubMed
  19.Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849–57.CrossRef PubMed
  20.Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–54.CrossRef PubMed PubMedCentral
  21.Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Possum MA, et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–55.CrossRef PubMed
  22.Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Hoffer G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–406.CrossRef PubMed
  23.Yokota S, Imagawa T, Mori M, Miyamae T, Amhara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.CrossRef PubMed
  24.De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.CrossRef PubMed
  25.Pagnini I, Savelli S, Matucci-Cerinic M, Fonda C, Cimaz R, Simonini G. Early predictors of juvenile sacroiliitis in enthesitis-related Arthritis. J Rheumatol. 2010;37:2395–401.CrossRef PubMed
  26.Bugos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthitis Res Care (Hoboken). 2015;67:1503–12.CrossRef
  27.Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriasis arthritis: a randomized trial. Lancet. 2000;356:385–90.CrossRef PubMed
  28.Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriasis arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89.CrossRef PubMed
  29.Antoni CE, Kavanaugh A, van der Hejide D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriasis arthritis: finding of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869–76.PubMed
  30.Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladden D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriasis arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–86.CrossRef PubMed
  31.Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ. Long-term safety and efficacy of rilonacept in patient with systemic juvenile arthritis. Arthritis Rheum. 2013;65:2486–96.CrossRef PubMed
  32.De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol. 1998;25:203–7.PubMed
  33.Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38:575–84.CrossRef PubMed
  34.Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL-6R in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomized SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626–34.CrossRef PubMed PubMedCentral
  35.Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomized, 2-part (proof-of-concept and dose- finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:1616–25.CrossRef PubMed PubMedCentral
  36.Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, et al. A phase II, double-blind, randomized, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71:1183–9.CrossRef PubMed
  37.Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Invest Drugs. 2014;23:1067–77.CrossRef
  38.O’Sullivam LA, Lioungue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol. 2007;44:2497–506.CrossRef
  39.LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, et al. JAK inhibition with tofacitinib suppresses arthritis joint structural damage through decreased RANKL production. Arthritis Rheum. 2012;64:3531–42.CrossRef PubMed
  40.Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connel CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.CrossRef PubMed
  41.van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcìa Meijide JA, Wagner S, et al. Tofacitinib or adalimuamb versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19.CrossRef PubMed
  42.Berhan A. Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double blind controlled studies. BMC Muscoloskelet Disord. 2013;14:332.
  43.Fleishmann RM, Damjanov NS, Kibitz AJ, Legedza A, Hoock T, Kinnman N. A randomized double-blind placebo-controlled, twelve-week, dose-ranging study on decernotinib, an oral selective JAK3 inhibitor, as monotherapy in patient with active rheumatoid arthritis. Arthritis Rheum. 2015;67:334–43.CrossRef
  44.McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriasis arthritis: 1 year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780–9.CrossRef PubMed
  45.Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL12/23 p40 monoclonal antibody, ustekinumab, in patient with active psoriatic arthritis despite conventional nonbiological and biological anti tumor necrosis factor therapy; 6-month and 1-year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990–9.CrossRef PubMed PubMedCentral
  46.Schafer P. Apremilast mechanism of action and application to psoriasis arthritis. Biochem Pharmacol. 2012;83:1583–90.CrossRef PubMed
  47.Kavanaugh A, Mease P, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladden DD, et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trail with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–6.CrossRef PubMed PubMedCentral
  48.Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomized, double-blind, multi center, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab (INX) in patient with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–12.CrossRef PubMed PubMedCentral
  49.Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: result from the SUNRISE trial. J Rheumatol. 2010;37:917–37.CrossRef PubMed
  50.Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;(1):CD007356.
  51.Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–806.CrossRef PubMed
  52.Narvàez J, Diaz-Tornè C, Juanola X, Geli C, Llobet JM, Nolla JM, et al. Rituximab therapy for refractory systemic onset juvenile idiopathic arthritis. Ann Rheum Dis. 2009;68:607–8.CrossRef PubMed
  53.Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonist. J Clin Rheumatol. 2009;15:363–5.CrossRef PubMed
  54.NHS England clinical reference group for paediatric medicine. Interim clinical commissioning policy statement: biologic therapies for the treatment of juvenile idiopathic arthritis (JIA). 2015. https://​www.​engage.​england.​nhs.​uk/​consultation/​specialised-services-policies/​user_​uploads/​biolgcs-juvenl-idiop-arthrs-pol.​pdf .
  55.Felquer ML, Soriano ER. New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug Administration. Curr Opin Rheumatol. 2015;27:99–106.CrossRef PubMed
  56.McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24 week, randomized, double blind, placebo controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73:349–56.CrossRef PubMed
  57.McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double blind, placebo controlled, phase3 trial. Lancet. 2015;386:1137–46.CrossRef PubMed
  58.Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–39.CrossRef PubMed
  
• 作者单位：Ilaria Pagnini (1)
  Federico Bertini (1)
  Rolando Cimaz (1)
  
  1. AOU Meyer, Viale Pieraccini 24, 50139, Florence, Italy
  
• 刊物主题：Pediatrics; Pharmacotherapy; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-2019

文摘

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood and is usually treated with non-steroidal anti-inflammatory drugs or disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate or sulfasalazine. However, not all patients respond to these treatments, and toxicities may limit long-term use or diminish compliance. With advances in pharmacotherapy and the development of new therapeutic agents, there have been improvements in treatment of both systemic and non-systemic JIA, particularly with biologic agents such as anti-tumor necrosis factor (TNF)-α, anti-interleukin (IL)-1, and anti-IL6. Anti-cell therapies, such as co-stimulator blockers or anti-CD20, small molecules, and biosimilars represent new areas of interest, and, while many are not yet currently commercially available for use in children, preliminary studies appear to be promising. In the present article, the authors review therapeutic strategies for the different JIA subtypes, mainly according to guidelines and recommendations. Newer and possible future treatments for arthritis, already approved in adults but currently under study in children, are also discussed. Drugs currently in development plans for rheumatoid arthritis, which hopefully will also be useful for JIA patients in the future, are also mentioned in this paper.